2024-518440-20-00RecruitingPhase 1
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of T7-010 in Healthy Participants.
T7 Therapeutics Inc.1 site in 1 country32 target enrollmentStarted: May 27, 2025Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Enrollment
- 32
- Locations
- 1
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Caroline Fortier
Scientific
T7 Therapeutics Inc.
Study Sites (1)
Loading locations...
Similar Trials
Terminated
Phase 1
A study to evaluate safety and tolerability of GS -5801 in healthy subjectsHepatitis B VirusInfection - Other infectious diseasesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12616001260415Gilead Sciences, Inc.70
Withdrawn
Phase 1
A Study of ELVN-002 in Healthy Adult Volunteers: Part BNon-small Cell lung canceron-small Cell lung cancerCancer - Lung - Non small cellACTRN12623000431628Enliven Therapeutics, Inc.6
Withdrawn
Not Applicable
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Injection of ABT-110 in Healthy Volunteers and Subjects with Chronic Low Back Paichronic low back pain10028302NL-OMON36923Abbott30
Completed
Phase 1
A phase 1 clinical trial of BIL06v/Alhydrogel to evaluate the safety, tolerability, immunogenicity and anti-tumour activity and to determine the most effective dose of BIL06v/Alhydrogel to treat patients with advanced forms of solid cancersAdvanced Solid CancersCancer - Any cancerACTRN12618000838213Biosceptre (Aust) Pty Limited29
Not yet recruiting
Not Applicable
A Phase 1 Study to Evaluate the Safety, Tolerability and Efficacy of MK-8353 Combination Therapies in Subjects With Advanced Solid Tumorsadvanced solid tumor10017991NL-OMON37039Merck Sharp & Dohme (MSD)24